Stanford study reports sustained mental health outcomes one year after magnesium-ibogaine treatment

A follow-up study conducted by researchers at Stanford Medicine has tracked 25 U.S. special operations veterans who received magnesium-ibogaine treatment. The findings indicate that, on average, participants reported lower levels of disability, PTSD, depression, and anxiety one year post-treatment compared to their pre-treatment baseline.

The cohort was previously documented in a 2024 Nature Medicine study that noted improvements in cognitive function and mental health just one month after the intervention. However, current researchers note that the study design faces significant limitations, including a small sample size and the absence of a control group. Because 23 of the 25 participants pursued additional psychedelic treatments or counseling during the year, the study cannot definitively attribute the long-term outcomes to the initial ibogaine treatment alone.

Ibogaine remains unapproved by the FDA and carries risks, including potentially fatal heart rhythm complications. While the study provides data for ongoing discussions about psychedelic-assisted therapy for veterans, the medical community maintains that further rigorous, large-scale controlled clinical trials are required to establish safety and efficacy standards.